Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01429)
Name
Sincalide
Synonyms    Click to Show/Hide the Synonyms of This API
Sincalide; 25126-32-3; CCK-8; SQ 19844; UNII-M03GIQ7Z6P; cholecystokinin C-terminal octapeptide; CHEMBL1121; M03GIQ7Z6P; H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2; 3-10-Caerulein, 5-L-methionine-; MFCD00079849; Kinevac; cholecystokinin 8; DSSTox_CID_28543; DSSTox_RID_82815; DSSTox_GSID_48617; (Tyr[SO3H]27)Cholecystokinin fragment 26-33 Amide; Sincalidum; Sincalida; Syncalide; (3S,6S,9S,15S,18S,21S)-9-((1H-indol-3-yl)methyl)-21-amino-3-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosanedioic acid; CAS-25126-32-3; Human CCK-8; CCK-8 (sulphated); Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2; Sincalidum [INN-Latin]; Sincalida [INN-Spanish]; Cholecystokinin octapeptide; Pancreozymin; SQ-19844; Sincalide [USAN:USP:INN:BAN]; NCGC00183278-01; NCGC00183363-01; C49H62N10O16S3; EINECS 246-639-0; Kinevac (TN); Sincalide (USAN/INN); Caerulein, 1-de(5-oxo-L-proline)-2-de-L-glutamine-5-L-methionine-; CCK C-terminal octapeptide; Cholecystokinin-pancreozymin; cholecystokinin fragment 26-33 amide (sulphated); GTPL864; SCHEMBL122365; CCK-8(SO3); DTXSID7048617; BDBM21147; CHEBI:135946; Pancreozymin C-terminal octapeptide; [125I]CCK-8; 1-De(5-oxo-L-proline)-2-de-L-glutamine-5-L-methioninecaerulein; HY-P0093; Tox21_112955; Tox21_113481; Cholecystokinin Octapeptide, sulfated; CORALYNECHLORIDEHYDRATE,98+%; AKOS016340423; CS-5963; DB09142; HS-2026; NCGC00167273-01; L-alpha-Aspartyl-O-sulfo-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; L-Aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide hydrogen sulfate (ester); O411; Cholecystokinin, CCK Octapeptide (26-33); D05845; Asp26-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-PheNH2; 126S323; A817659; Cholecystokinin Octapeptide (sulfated) ammonium salt; Q7521885; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid; (3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid; (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-(methylthio)-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-(methylth; (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methyls; (3S)-3-azanyl-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-azanyl-1-oxidanylidene-3-phenyl-propan-2-yl]amino]-4-oxidanyl-1,4-bis(oxidanylidene)butan-2-yl]amino]-4-methylsulfanyl-1-oxidanylidene-butan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxidanyl; (3S,6S,9S,15S,18S,21S)-9-((1H-indol-3-yl)methyl)-21-amino-3-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic acid; (3S,6S,9S,15S,18S,21S)-9-((1H-indol-3-yl)methyl)-21-amino-3-((S)-1-amino-1-oxo-3-phenylpropan-2-ylcarbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic acid
Clinical Status
Approved
PubChem CID
9833444
Formula
C49H62N10O16S3
Canonical SMILES
CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
InChI
1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
InChIKey
IZTQOLKUZKXIRV-YRVFCXMDSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=9833444"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 1143.3 Topological Polar Surface Area 486
XlogP -2.6 Complexity 2180
Heavy Atom Count 78 Rotatable Bond Count 33
Hydrogen Bond Donor Count 13 Hydrogen Bond Acceptor Count 19
Full List of Drug Formulations (DFMs) Containing This API
          Sincalide 0.005mg/vial injectable Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Arginine Hydrochloride; Lysine Hydrochloride; Mannitol; Methionine; Pentetic Acid; Polysorbate 20; Potassium Phosphate Dibasic; Sodium Metabisulfite
                   Dosage Form Injectable
                   Company Bracco
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [1]
Methionine DIG Info Integral membrane E16 (IC50 = 120000 nM) [2]
Arginine DIG Info GPCR33 receptor (EC50 = 284000 nM) [3]
Polysorbate 20 DIG Info Cytochrome P450 2E1 (IC50 = 64.1 uM) [4]
References
1 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
2 Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). J Med Chem. 2018 Aug 23; 61(16):7358-7373.
3 A highly selective agonist for the metabotropic glutamate receptor mGluR2. Med Chem Comm. (2011) 2:1120-1124.
4 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.